{
  "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
  "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 52,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "The table highlights the clinical gap in patients with prior kinase inhibitor treatment, specifically those with G2032R mutations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/10",
  "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
  "deckJsonHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7.json",
  "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.015,
        "w": 0.51,
        "x": 0.076,
        "y": 0.905
      },
      "kind": "source-note",
      "text": "Sources: Lin et al., J Thorac Oncol 2017; Gainor et al, JCO Precision Oncol 2017; Ou and Zhu Lung Cancer 2019; Patil et al, JTO 2018",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54314b1e-8f91-4710-ba26-84c58b9b3f63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.864,
        "x": 0.068,
        "y": 0.35
      },
      "kind": "table",
      "text": "Line of therapy, Sub-population, Incidence (US), CNS disease, Standard of care (2022)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9fb0d51-61fc-411e-a251-ac1030a985b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.68,
        "x": 0.076,
        "y": 0.185
      },
      "kind": "title",
      "text": "Emerging resistance mutations and increasing CNS involvement limit utility of approved therapies",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd207267-c957-4b47-be2b-ca12b61029d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.415,
        "x": 0.076,
        "y": 0.115
      },
      "kind": "title",
      "text": "ROS1-positive NSCLC Market Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d324b7ec-4343-4098-8719-0ce7e351549b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "ebbf364b-ffa0-40d4-80ae-1342bf293c32",
      "evidence": "ROS1-positive NSCLC Market Overview",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "d3ae7f4b-031a-4e4e-8043-334fae7384f3",
      "evidence": "Segments market by clinical characteristics and treatment history",
      "confidence": 0.7
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 10,
      "beatId": "cf20fd65-cc92-446c-a986-52f3ef139fce",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Sizing",
      "beatSlug": null,
      "evidence": "Slide 10: ROS1-positive NSCLC Market Overview.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5e62d3b3-7d2f-4957-9be3-165db6a30ea2",
      "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions.",
      "position": 0,
      "objective": "What are the consequences of not addressing drug resistance in cancer treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}